We thank all the speakers of the Chile 2016 Sessions who shared their presentations to contribute to our mission of promoting the dissemination of information from research and clinical practice in Interventional Cardiology. You can read and/or download them below Lluberas, Ricardo. “Role of pharmacovasive therapy in the treatment of IAMcEST. Implications for Latin<a href="https://solaci.org/en/2017/01/07/see-the-presentations-of-the-2016-chile-sessions/" title="Read more" >...</a>
The aim of this meta-analysis, which included all randomized studies carried out to date, was to compare an early invasive strategy vs. a delayed invasive strategy in patients undergoing non ST elevation myocardial infarction (NSTEMI). Even though there is no doubt invasive strategies reduce events rate such as death and re-infarction in NSTEMI patients,<a href="https://solaci.org/en/2016/12/19/post-nstemi-invasive-strategy-timing/" title="Read more" >...</a>
Courtesy of Dr. Agustín Vecchia. In treating bifurcations, the provisional stenting strategy continues to be preferred. However, a percentage of these lesions must be treated with two stents, which involves different techniques. In provisional stenting, when two stents are required, a recent consensus document of the European Bifurcation Club has recently recommended the TAP<a href="https://solaci.org/en/2016/09/14/culotte-vs-tap-in-bifurcations-which-is-better/" title="Read more" >...</a>
Courtesy of Dr. Guillermo Migliaro. Fractional flow reserve (FFR) is the radio of two flows expressed as the ratio of two pressures ─ distal pressure across stenosis (Pd) to aortic pressure (pa) ─ obtained only under maximal coronary hyperemia, which is a state of drug induced maximal vasodilation. The gold standard to create<a href="https://solaci.org/en/2016/09/12/contrast-induced-ffr-cost-and-time-effective-alternative/" title="Read more" >...</a>
Courtesy of Dr. Rodrigo Abreu. INTRODUCTION Bifurcation lesion treatment has evolved considerably in the last years: from balloon angioplasty (with high occlusion and restenosis rates) to bare metal stent angioplasty (with a procedural success around 86% and major adverse cardiac events [MACE] at 1 year around 32%). The subsequent emergence of drug-eluting stents (DES) reduced<a href="https://solaci.org/en/2016/09/09/xience-v-safe-in-real-life-bifurcation-lesions/" title="Read more" >...</a>
Original Title: Treatment of Symptomatic Severe Aortic Stenosis with a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. Reference: Ganesh Manoharan et al. J Am Coll Cardiol Intv. 2015; 8(10):1359-1367. Courtesy of Dr. Agustín Vecchia. Despite the rapid growth and evolution of transcatheter aortic valve replacement devices (TAVR), vascular access complications, paravalvular leak, stroke<a href="https://solaci.org/en/2016/07/08/medtronics-new-corevalve-evolut-r-for-tavr/" title="Read more" >...</a>
Original Title: Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I) 2-Year Clinical and Imaging Results CME. Reference: Johannes Lammer et al. J Am Coll Cardiol Intv. 2016;9(11):1178-1187. This is the first study on humans to assess the bioresorbable everolimus eluting vascular scaffold for the treatment of peripheral artery disease involving<a href="https://solaci.org/en/2016/06/29/bvs-safe-also-in-peripheral-territory/" title="Read more" >...</a>
Original Title: Incidence and Clinical Outcome of Stent Fractures on the Basis of 6555 Patients and 16482 Drug Eluting Stents From 4 Centers. Reference: Kan J et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1115-23. Courtesy of Dr. Guillermo Migliaro. Stent fracture (SF) has been associated with instent restenosis (ISR), stent thrombosis (ST) and repeat revascularization<a href="https://solaci.org/en/2016/06/28/stent-fracture-more-frequent-than-expected/" title="Read more" >...</a>
Original Title: Percutaneous coronary intervention for chronic total occlusion of the coronary artery with implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry. Reference: Maciej Lesiak, et al EuroIntervention 2016;12:e144-e151 Courtesy of Dr. Carlos Fava. Chronic total occlusion (CTO) is a real challenge and have a success rate of around 80% with trained<a href="https://solaci.org/en/2016/06/17/chronic-total-occlusions-pilot-experience-with-bvs/" title="Read more" >...</a>
Original Title: Angiographic and Clinical Outcomes After Everolimus-Eluting Stenting for Unprotected Left Main Disease and High Anatomic Coronary Complexity. Reference: JACC Cardiovascular Interventions. Doi: 10.1016/j.jcin.2016.02.016. Courtesy of Dr. Agustín Vecchia. In patients with unprotected left main disease (ULMD) associated to complex coronary anatomy, choosing a revascularization strategy can be challenging. Current guidelines recommend surgery for<a href="https://solaci.org/en/2016/06/06/left-main-pci-requiem-for-the-syntax-score/" title="Read more" >...</a>